HSV Vaccine Evaluation in Mice
Author Information
Author(s): Elisa Rossetti, Marija Vujadinovic, Ella van Huizen, Jeroen Tolboom, Hanneke Schuitemaker, Feng Yao, Roland Zahn, Eirikur Saeland
Primary Institution: Janssen Vaccines & Prevention, Leiden, The Netherlands
Hypothesis
Can a replication-incompetent adenoviral vector encoding for HSV-2 gD2 provide immunogenicity and protection against HSV-2 infection in mice?
Conclusion
The Ad35.HSV.gD2 vaccine induced robust immune responses and provided complete protection against HSV-2 in mice.
Supporting Evidence
- Immunization with Ad35.HSV.gD2 resulted in 100% survival against HSV-2 challenge.
- Significantly higher virus neutralizing antibody titers were observed in the two-dose regimen.
- Viral shedding was significantly lower in immunized mice compared to controls.
Takeaway
Researchers created a vaccine to protect mice from a virus that causes genital herpes, and it worked really well!
Methodology
Mice were immunized with the Ad35.HSV.gD2 vaccine and then challenged with HSV-2 to assess immune response and protection.
Potential Biases
Potential bias due to the involvement of authors affiliated with vaccine development companies.
Limitations
The study was conducted in mice, which may not fully predict human responses.
Participant Demographics
Female BALB/c mice, aged six to eight weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website